Bella Kachkoff Zubkov, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 210 New London Tpke, Glastonbury, CT 06033 Phone: 860-633-1543 Fax: 860-659-9755 |
Athanasia D Syrengelas, MD PHD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 210 New London Tpke, Glastonbury, CT 06033 Phone: 860-633-1543 Fax: 860-659-9755 |
James Stephen Rosokoff, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 15 Concord Street, Glastonbury, CT 06033 Phone: 860-659-2779 Fax: 860-633-9315 |
Janelle Shield Manton, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 210 New London Turn Pike, Glastonbury, CT 06033 Phone: 860-633-1543 Fax: 860-659-9755 |
Ali Banki, D.O. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2928 Main St Ste 200, Glastonbury, CT 06033 Phone: 860-659-2779 Fax: 860-633-9315 |
Penny Ann Lowenstein, MD Dermatology Medicare: Medicare Enrolled Practice Location: 210 New London Tpke, Glastonbury, CT 06033 Phone: 860-633-1543 Fax: 860-659-9755 |
News Archive
Applied DNA Sciences Inc. announced today that LineaRx, Inc., its wholly-owned subsidiary focused on next-generation biotherapeutics, has signed a Joint Development Agreement with Takis S.R.L. and Evvivax S.R.L., biotechnology companies focused on the discovery and development of DNA based anti-cancer vaccines for the human and animal markets, respectively.
Children and young adults who receive CAR T-cell therapy for the most common childhood cancer - acute lymphoblastic leukemia - suffer remarkably fewer relapses and are far more likely to survive when the treatment is paired with a subsequent stem cell transplant, a new study finds.
The Health and Human Services Department on Monday launched a new component of its effort to make health care better and more efficient. HHS announced its "Innovation Advisors" program, through which it will select as many as 200 experts to work with doctors and other providers on ways to improve the health care delivery system.
VitaPath Genetics, a molecular diagnostics company, announced today that it has closed a $6 million series A round of funding led by MDV-Mohr Davidow Ventures. VitaPath was originally seeded by X/Seed Capital, which also co-invested in the Series A. Concurrent with the financing MDV's Michael Goldberg and X/Seed's Michael Borrus took seats on the company's board.
Researchers from China and Canada recently combined structural data obtained from cryo-EM and structure prediction and constructed bottom-up Martini coarse-grained models of intact envelopes of SARS-CoV and SARS-CoV-2.
› Verified 5 days ago